Abstract: Biomolecular screening is now a crucial component of the drug discovery process, and this glossary will be of use to practitioners in the field of screening and to those who interact with the screening community. The glossary contains definitions related to various aspects of the screening process such as assay types, data handling, and relevant technologies. Many of the terms used in this discipline are not covered by existing glossaries, and where they are, the definitions are often not appropriate for this field. Where appropriate, this document provides new or modified definitions to better reflect the new context. The field of biomolecular screening is multidisciplinary in nature, and this glossary, containing authoritative definitions, will be useful not only for regular practitioners, but also for those who make use of data generated during the screening process.
INTRODUCTION
The term "biomolecular screening" became widely used in the late 1980s to broadly describe a new and rapidly adopted process for lead identification in drug discovery. This new process involved screening natural product extracts and/or amassed compound collections, typically from pharmaceutical companies, in a random, unbiased manner to identify novel modulators of biological targets. This was in contrast to the then standard process of rational, directed design and screening of compounds according to available target information. The capacity for random screening increased from thousands of samples to tens of thousands (high-throughput screening or HTS) to even a hundred thousand (ultra-highthroughput screening or UHTS) samples per day as compound libraries were assembled into readily accessible formats and as combinatorial chemistry was applied to increase the size of compound collections. The screens encompassed bioassays that could be cell-based or purely biochemical in nature, and the need to screen increasing numbers of samples as time progressed, fostered the development of many new assay formats.
The Society for Biomolecular Sciences (SBS) was formed in 1994 (originally as the Society for Biomolecular Screening) to disseminate best practices and encourage the development of new technologies to meet the needs of the field. As with any emerging area, many new terms emerged to reflect new assay formats and new processes leading from initial testing through lead optimization. With this glossary, IUPAC, in conjunction with SBS and with additional input from the International Union of Basic and Clinical Pharmacology (IUPHAR), brings together definitions of common terms used in the field of biomolecular screening.
The terms included in this glossary span a range of disciplines which contribute to the early phases of drug discovery. Appropriate IUPAC recommendations have been consulted and used. For some entries, alternative definitions are given in order to display the significant differences in use that occur in this phase of the drug discovery process. In constructing this glossary, efforts have been made to give a complete list of relevant terms. However, for such a relatively new field, it is difficult to guarantee that all useful terms have been included. The authors intend to collect additional terms in anticipation of a future updated glossary.
We are grateful to all those whose names are listed in the acknowledgment section, to members of the IUPAC Chemistry and Human Health Division and to the reviewers; these individuals provided invaluable contributions to the glossary as it worked its way from initial assembly through final review.
GLOSSARY OF TERMS
absorbance assay optical density assay (obsolete) Assay in which response is determined by the detection of light absorption by an assay component.
Note:
The concentration of the absorbing species can be quantified using the Beer-Lambert law (or Beer-Lambert-Bouguer law) where ε is the molar absorption coefficient of the absorbing species, l is the absorption path length, and c the amount concentration. A sample is irradiated with a specific wavelength of light, typically in the ultraviolet or visible spectral region; the spectral radiant power of incident light on the sample (P 0 ) and transmitted radiation after passing through the sample (P) are used to calculate absorbance (A).
allosteric site
Binding site on a protein, distinct from the site recognized by an endogenous agonist (i.e., the orthosteric site) in the case of a receptor, or substrate in the case of an enzyme, that when occupied by a ligand effects a conformational change in the protein, thus altering its signaling, catalytic properties, or its capability to interact with other macromolecules.
antagonist Drug or compound that opposes the physiological effects of another.
Note 1:
At the receptor level, it is a chemical entity that opposes the receptor-associated responses normally induced by another bioactive agent.
Note 2:
This term does not imply a specific mechanism that may be competitive, allosteric, noncompetitive, or physiological.
Note 3:
Antagonist potency is often expressed as pA2, the negative logarithm to base 10 of the molar concentration of an antagonist that makes it necessary to double the concentration of the agonist needed to elicit the original submaximal response obtained in the absence of antagonist [5] .
Note 4: Updated from current "Gold Book" entry. [3, 4] artefact artifact (variant spelling), see any dictionary Observation, effect, or result that is inaccurate because it is produced by the methodology used in scientific investigation or by experimental error. See also false positive, false negative.
[6] assay 1. n., Process of quantitative or qualitative analysis of a component of a sample. 2.
n., Results of a quantitative or qualitative analysis of a component of a sample. 3.
v., To carry out quantitative or qualitative analysis of a component of a sample. [6] assay validation Experiments conducted to verify that the output measurements of the assay are consistently reflective of the activity against the target.
Note:
Often referred to as a peripheral or peripheral device when it is an instrument incorporated into a module, a workstation, or a fully automated system.
Examples: liquid handler, module, workstation.
automation (in analysis) Mechanization with process control, where process means a sequence of manipulations. One or several functions in an analytical instrument may be automated. The corresponding adjective is "automated" and the verb is "automate". [3] average mean Arithmetic mean of a set of values.
background (in biomolecular screening) 1.
Magnitude of a signal produced in an assay or screen in the absence of a test substance.
2.
Signal detected from an assay in the absence of target activity; often equivalent to negative control. See also negative assay control, noise. batch Quantity of material which is known or assumed to be produced under uniform conditions. Some vocabularies assume "lot" and "batch" to be synonymous. The distinction made here with respect to knowledge of production history permits a lot to consist of one or more batches and is useful in interpreting the results of analysis. [3] binding assay Assay in which the specific physical association or interaction between two molecules (e.g., ligand-receptor, antibody-antigen, protein-protein, ligand-transport protein) is measured.
Note:
The assay can be homogeneous or heterogeneous, competitive or noncompetitive, and may be run at equilibrium or in kinetic mode. Appropriate assay controls and/or standard reagents are often needed to determine the specific binding in contrast to nonspecific adsorption processes.
binding isotherm
Graphical representation of the relationship between the amount of ligand that is specifically bound to a receptor per mass of binding material and the amount of free ligand.
Note 1: For a system containing a single binding site and lacking cooperative interactions, the binding isotherm is described by Note 2: A Scatchard plot [7] was formerly used to determine B max and K d . It is now more common to determine these parameters by nonlinear least-squares fitting to the binding equation given above.
Note 3:
The total number of receptors or binding sites in the system is proportional to B max .
cell-based assay
Assay in which the response of live cells to a test sample is measured. 
cell mortality
Ratio of counted dead cells to the total number of observed cells.
Note:
Dead cells are often counted using apoptosis or nuclear markers.
cell viability
Ratio of counted live cells to the total number of observed cells.
Note:
Live cells are often counted using nuclear, membrane, or metabolic markers.
channel blocker
Compound that reduces or eliminates the conductance of an ion channel by impeding the movement of ions through that channel.
Note:
Dihydropyridine antagonists such as nifedipine, which also block the conductance of some L-type calcium channels, are not classified as channel blockers since their action is to inhibit channel gating.
Example: verapamil, which blocks the conductance of some L-type calcium channels.
[8]
J. PROUDFOOT et al. © 2011 , IUPAC Pure Appl. Chem., Vol. 83, No. 5, pp. 1129 -1158 , 2011 channel opener channel activator Compound that increases the conductance of an ion channel by a mechanism other than alteration of membrane potential or activation of the cognate receptor.
Examples: retigabine, cromakalim.
cheminformatics
Use of mathematical and statistical methods to extract information from chemical data.
Note:
For screening purposes, cheminformatics approaches are used in order to design compound libraries for general screening or for screening against a specific target class. Cheminformatics is also used to cluster active molecules based on chemical similarity, which aids in the analysis of screening data.
[9]
chemotaxis assay Cell-based assay in which the rate and/or direction of cell migration is measured.
Typically, the response to a test sample is detected by means of a fluorescent probe or with label-free methods. Classical chemotaxis assays utilized the Boyden chamber and required manual counting of migrating cells under the microscope.
Population of genetically identical cells or organisms having a common ancestor.
2.
To produce such a population.
3.
Recombinant DNA molecules all carrying the same inserted sequence. [6] coefficient of variation See relative standard deviation.
combinatorial library
Set of compounds prepared by combinatorial chemistry. It may consist of a collection of pools, or sublibraries. Its composition may be described by the chemset notation. [10] competitive binding assay Molecular assay based on the competition between a ligand and a reference ligand for the same binding site on a receptor (e.g., antibody, transport protein).
compound collection compound library compound deck Set of chemicals that has been assembled and annotated for easy storage and retrieval and that is available for screening.
Note:
Generally consists of compounds synthesized by combinatorial or standard synthetic methods or purchased from commercial sources, or of natural products as pure samples.
Compounds may be stored in dry powder form, or dissolved at a fixed concentration in a solvent, such as dimethylsulfoxide.
compound deck
See compound collection.
compound library
concentration response relationship (in biomolecular screening) Association between compound concentration and the resultant magnitude of the continuously graded change produced, in an assay. Related terms:
confirmed hit Sample that produces activity above the hit threshold in an assay and whose structural identity has been confirmed.
counter-screen
Screen in which test samples are assessed against a target for unwanted activity.
Note:
This target may or may not be structurally or functionally related to the intended target.
cytotoxicity assay
Cell-based assay in which damage to cell structure or function caused by a test sample is determined. See also cell mortality, cell viability.
effective concentration (EC)
Concentration of a substance that causes a defined magnitude of response in a given system.
Note 1:
EC 50 is the median concentration that causes 50 % of the maximal response.
Note 2:
Usually refers to an agonist in a receptor system. The value of this quantity may result from either an increase or a decrease in a biological function.
See also inhibitory concentration. [6] J. PROUDFOOT et al.
efficacy (in receptor pharmacology) Extent to which a compound activates a receptor to produce a response in an assay under saturating conditions.
Note 1:
Usually compared to results with the positive and negative assay controls. When the compound produces a maximal signal that is 100 % of that of the positive control, it is said to be a full agonist and has high efficacy. When the effect plateaus with increasing concentration to reach an intermediary level of activity, the compound is said to be a partial agonist with lower efficacy.
Note 2: Due to the common overexpression of receptors in screening assays, it is not always possible to detect differences in efficacy among full agonists. A more accurate assessment of relative efficacy may require systems with lower receptor expression where it is often found that one agonist may show partial agonist character.
See also partial agonist.
electrochemiluminescence assay
Assay in which light emitted by electrogenerated luminescence is detected and used to quantify a label, e.g., ruthenium(II) tris-(bipyridine), on one of the two assay binding components. Example: Coated magnetic beads bind the protein target and are then captured in a flow cell of the detector where the energy state of the Ru is chemically converted to release a photon measured at 620 nm with a photomultiplier tube. There is little or no compound interference during detection because of the wash step within the flow cell. Generally not used for high-throughput screening but for secondary assays. See electrochemiluminescence in [3] . electrogenerated luminescence (ECL) electroluminescence electrochemilumininescence Luminescence produced by electrode reactions. [3] emission anisotropy degree of (polarization) anisotropy luminescence anisotropy Used to characterize luminescence (fluorescence, phosphorescence) polarization resulting from photoselection. Defined as where I || and I ⊥ are the intensities measured with the linear polarizer for emission parallel and perpendicular, respectively, to the electric vector of linearly polarized incident electromagnetic radiation (which is often vertical). The quantity I || + 2I ⊥ is proportional to the total fluorescence intensity I. . In many cases, it is preferable to use emission anisotropy because it is additive; the overall contribution of n components r i , each contributing to the total fluorescence intensity with a fraction f i = I i /I, is Note 2: On continuous illumination, the measured emission anisotropy is called steady-state emission anisotropy (r) and is related to the time-resolved anisotropy by where r(t) is the anisotropy and I(t) is the radiant intensity of the emission, both at time t following a δ-pulse excitation.
Note 3: Luminescence polarization spectroscopy, with linear polarizers placed in both beams, is usually performed on isotropic samples, but it may also be performed on oriented anisotropic samples. In the case of an anisotropic, uniaxial sample, five linearly independent luminescence spectra, instead of the two available for an isotropic sample, may be recorded by varying the two polarizer settings relative to each other and to the sample axis.
Note 4:
The term "fundamental emission anisotropy" describes a situation in which no depolarizing events occur subsequent to the initial formation of the emitting state, such as those caused by rotational diffusion or energy transfer. It also assumes that there is no overlap between differently polarized transitions. The (theoretical) value of the fundamental emission anisotropy, r 0 , depends on the angle α between the absorption and emission transition moments in the following way:
where < > denotes an average over the orientations of the photoselected molecules. r 0 can take on values ranging from -1/5 for α = 90° (perpendicular transition moments) to 2/5 for α = 0° (parallel transition moments). In spite of the severe assumptions, the expression is frequently used to determine relative transition-moment angles.
Note 5:
In time-resolved fluorescence with δ-pulse excitation, the theoretical value at time zero is identified with the fundamental emission anisotropy. In general, an enzyme catalyses only one reaction type (reaction specificity) and operates on only one type of substrate (substrate specificity). Substrate molecules are attacked at the same site (regiospecificity) and only one or preferentially one of the enantiomers of chiral substrates or of racemic mixtures is attacked (stereospecificity) [3] .
[6]
enzyme-linked immunosorbent assay (ELISA or EIA) Heterogeneous assay in which an antibody linked to an enzyme is used to detect the quantity of antigen present in a sample.
Note:
After binding of the enzyme-linked antibody to the antigen, either directly or indirectly via a second antibody, a subsequent reaction of the enzyme with a substrate yields a chromogenic or fluorogenic product that produces an amplified signal proportional to the concentration of the antigen.
epitope Any part of a molecule that acts as an antigenic determinant. A macromolecule can contain many different epitopes each capable of stimulating production of a different specific antibody. [3] epitope mapping Identification and localization of the specific regions of protein molecules that are recognized by the immune system.
equilibrium assay
Assay in which there is sufficient incubation time for the plateau phase of the signal to be reached and equilibrium has been established between the reactants.
false negative
Assay result in which a sample known to be active does not produce either the expected signal or a signal above the activity threshold.
Note:
A false negative can occur when an assay lacks appropriate discriminatory power, when the threshold is inappropriately set, or as a result of mistaken identity of the test sample. A false negative can also occur due to specific compound properties such as poor solubility, high nonspecific protein binding, or interference with the assay signal.
See also artefact, false positive.
false positive
Assay result in which a sample known to be inactive produces a signal or response above the activity threshold.
Note:
A false positive can occur when an assay lacks appropriate discriminatory power, when the threshold is inappropriately set, as a result of certain physical properties of the substance (e.g., a fluorescent compound in a fluorescence intensity assay, aggregation), or as a result of mistaken identity of the substance.
See also artefact, false negative.
flow cytometry assay
Cell-based assay in which the response is dependent on the detection of the phenotype of cells as determined through the light-scattering properties of each cell, and, typically, the fluorescence intensity of a relevant probe.
Note 1: Flow cytometry has been adapted to fluorescently labeled bead-based assays.
Note 2:
In fluorescence-activated cell sorting, single cells are rapidly passed through a channel where they are optically analyzed and separated based on the specific light-scattering and fluorescent characteristics of each individual cell.
flow injection (flow analysis)
The introduction of a sample or reagent into a continuous stream by use of a rapid delivery device. [3] Note:
For an expanded definition, see [12] .
fluorescence Luminescence which occurs essentially only during the irradiation of a substance by electromagnetic radiation. [3] fluorescence correlation assay Assay in which fluctuations in fluorescence intensity are detected and used to characterize a species that is labeled with a fluorescent probe.
Note:
The fluctuations are measured for a small volume of the total assay sample and are attributed to local diffusion of the probe in the detected volume or interactions that change the quantum yield of fluorescence.
J. PROUDFOOT et al.
fluorescence polarization, p Dimensionless value determined from the fluorescence intensities (I) measured parallel (I || ) and perpendicular (I ⊥ ) to the excitation plane:
Note:
Fluorescence anisotropy (r) differs only in normalization and is determined from r = (I || -I ⊥ ) / (I || + 2I ⊥ ) [1] See also emission anisotropy, fluorescence polarization assay.
fluorescence polarization assay
Assay in which the association between an intrinsically fluorescent ligand, or a ligand linked to a fluorescent probe, and a larger macromolecule is detected.
Note:
The degree to which the labeled ligand depolarizes plane-polarized light is directly proportional to the rate at which it tumbles in solution. Tumbling will be slower when the ligand is associated with the larger macromolecule as compared to free in solution, consequently resulting in a lower degree of depolarization.
See also fluorescence polarization, homogeneous binding assay.
fluorescence resonance energy transfer (FRET) assay
Assay based on the nonradiative energy transfer that occurs when the emission spectrum of a fluorescent donor molecule overlaps with the absorption spectrum of an energy acceptor molecule.
Note 1:
The donor and the acceptor fluorophores are linked directly or indirectly to two binding partners, and energy transfer occurs when the fluorophores are in close proximity with proper alignment of donor and acceptor electronic dipoles, i.e., when the binding partners interact.
Note 2:
The fluorophores can be either of small molecule or protein nature.
Note 3:
Use of a donor with a long fluorescence lifetime allows time-delayed (or time-resolved) fluorescence measurement (TR-FRET), providing conditions where other fluorophores in the assay medium are not detected.
functional assay
Assay in which the biological or physiological activity of the target is measured. Example: An assay in which an agonist stimulates, in receptor-transfected cells, the production of a second messenger, such as cAMP or Ca 2+ , which is detected with a fluorescence readout.
G protein-coupled receptor (GPCR)
Family of transmembrane receptors that connects directly to a family of GTP binding protein/GTPases for signal transduction. 
heterogeneous binding assay
Assay in which one binding component is immobilized to a surface (e.g., cellular membrane, glass, gold, bead, or biopolymer layer) while its binding partner is freely diffusible.
Note 1:
The extent of interaction between the binding partners is determined after their physical separation, which is usually achieved by filtration, centrifugation, magnetic field, or chromatography.
Note 2: Used to qualitatively discriminate specific and non-specific interaction or quantitatively determine the concentration of a component part of a mixture.
high-content screening assay
A cell-based assay that produces multiple biological readouts.
Note:
Most commonly used in relation to the mathematical (quantitative) analysis of an image acquired using an automated microscope. Analysis algorithms are used to quantify cellular parameters (e.g., number, motility, neurite outgrowth, size, shape) and subcellular events (e.g., receptor internalization, protein translocation, protein expression nuclei shape).
high control
See positive assay control.
high-performance liquid chromatography (HPLC) assay
Assay in which response is determined after the physical separation of assay components using highperformance liquid chromatography (HPLC) with concurrent detection, usually by monitoring absorbance at an appropriate wavelength.
Note:
Changes in the concentration of assay components at one or more times over the course of the assay can be determined by the relative area under the detection peaks as compared to assay controls and standards.
high throughput (in biomolecular screening) Relative term, applied to the generation of a large number of results in a short timeframe (e.g., 10 5 in a week or a month).
Usually achieved by employing some degree of automation.
See also ultra-high throughput.
high-throughput screening (HTS)
Method in which a large number of assays (from thousands to millions) is performed and assessed in a relatively short time period.
J. PROUDFOOT et al.
Note 1:
Typically, these assays are carried out in microplates of at least 96 wells using automated or robotic technologies.
Note 2:
The rate of at least 10 5 assays per day has been termed ultra-high-throughput screening (UHTS).
hit Sample that produces activity above the hit threshold in an assay. See also active.
hit rate Proportion of hits from a screen that displays confirmed activity beyond a minimum defined level, the hit threshold. It is expressed as a percentage of the number of samples screened.
hit threshold
Minimum activity that defines actives in a primary screen.
Note 1: It is usually expressed as percentage of inhibition or stimulation relative to assay controls.
Note 2:
A widely used hit threshold is 50 % inhibition. A more statistically meaningful and equally common threshold is 3 standard deviations from the mean.
homogeneous assay
Assay in which all reagents and reactants are of a uniform phase (typically, liquid phase) and assay response is detected without the need for physical separation of assay components. See also heterogeneous assay.
homogeneous binding assay
Single-phase system used to qualitatively discriminate between specific and nonspecific interactions or quantitatively determine the concentration of a component part of a mixture. Example: fluorescence polarization assay.
image-based assay
Assay in which image analysis algorithms that determine the compartmentalization of fluorescent probes give topological as well as quantitative information.
Note:
The use of automated cellular imaging for screening has been made possible by the development of digital imaging technology.
See also high-content screening.
immobilized metal ion affinity-based fluorescence polarization (IMAP TM ) assay
Assay in which the interaction between nanoparticles coated with triply charged metal ions and phosphate groups on a substrate that carries a fluorescent tag is detected.
Note 1:
The phosphorylated fluorescent substrate bound to the nanoparticle will exhibit high fluorescence polarization relative to the unbound (unphosphorylated) peptide substrate.
Note 2:
Used for kinase assays where a phosphate group is added to a peptide substrate or for phosphatase assays where the phosphate is removed from a peptide substrate.
See also fluorescence polarization.
inactive, n., adj. (in biomolecular screening)
Sample that, at the tested concentration, does not produce a response above the hit threshold in an assay.
Note:
A sample may also be designated as inactive when attempts to confirm an active fail.
See also artefact, false positive, hit.
indirect binding assay
See noncompetitive binding assay.
Equilibrium dissociation constant of an enzyme-inhibitor complex:
The equilibrium dissociation constant of a receptor-ligand complex.
Note:
This value is usually obtained through competition binding experiments, where K i is determined after the IC 50 obtained in a competition assay performed in the presence of a known concentration of labeled reference ligand which has a known dissociation constant, for the target.
[13]
inhibitor (in biomolecular screening) 1.
Substance that decreases the rate of an enzyme-catalyzed reaction.
2.
Substance that decreases the rate of a process mediated by a transporter protein.
3.
Substance that decreases the extent of interaction between a ligand and its target.
Note:
Characterized by an IC 50 . For enzyme-catalyzed reactions, the mechanism of inhibition can be assigned by experimentation. The two most commonly encountered mechanisms involve either competition with one of the substrates to occupy the active site (competitive inhibition), or binding at an alternative site inducing conformational changes in the active site (allosteric inhibition). Independently from the site of action, inhibitor binding can be reversible (the on and off rates are such that dissociation of the inhibitor occurs rapidly in relation to the timescales employed in the assay) or irreversible (most often covalent, as in the case of "suicide substrates" which bind covalently to the active site upon activation by an enzyme). [14] inhibitory concentration (IC) Concentration of a substance that causes a defined inhibition of a given system. [6] Note 1: IC 50 is the median concentration that causes 50 % inhibition.
Note 2:
The IC 50 value is influenced by the experimental conditions (e.g., substrate or agonist concentration) which should be specified.
See also effective concentration, inhibition constant, K i .
inverse agonist
Ligand that decreases signaling through a receptor below the level of constitutive activity.
Note:
Several receptors, especially when expressed at high levels, exhibit constitutively active signaling. Demonstrating an inverse agonist effect is dependent upon the constitutive activity of the particular receptor which is manifested in the absence of a conventional agonist. Upwards of 85 % of antagonists identified in screens of GPCRs are actually inverse agonists.
See also agonist, partial agonist, antagonist. [15] in vitro In glass, referring to a study in the laboratory usually involving isolated organ, tissue, cell, or biochemical systems.
See also in vivo. [3] in vivo In the living body, referring to a study performed on a living organism. [3] See also in vitro.
isotopes Nuclides having the same atomic number but different mass numbers. See also radioisotope, isotopic labeling, radioligand. [3] isotopically labeled Describes a mixture of an isotopically unmodified compound with one or more analogous isotopically substituted compound(s). See also isotope, radioligand, probe. [3] kinetic assay Assay in which the time dependence of the signal intensity is measured. Signal values are typically acquired at several time intervals in order to calculate kinetic parameters.
Kinetic assays are generally designed such that the change in signal with time is linear throughout the experiment.
See also equilibrium assay, end-point assay. See also isotopic labeling.
label-free assay
Assay in which there is no requirement to modify one of the interacting components in order to facilitate signal detection.
Note:
Used to monitor macromolecule/macromolecule or small-molecule/macromolecule binding, as well as cell adhesion or cell signaling.
Examples: Assays in which calorimetry, mass spectrometry, or nuclear magnetic resonance provides the signal.
label-free detection
Direct detection of compound activity on a target without the requirement for a labeled reagent.
Examples: Use of calorimetry, mass spectrometry, surface plasmon resonance, or nuclear magnetic resonance to measure a signal.
laboratory information management systems (LIMS)
Computerized system designed to provide on-line information about the samples analyzed in a laboratory.
Note 1: Information provided may include the current location of each sample in the laboratory, the method and status of each analysis, and experimental data and calculated results.
Note 2: Typically, LIMS connect analytical instruments to one or more personal computers and manage processes from sample log-in to reporting test results. With interfaces to enterprise resource planning or manufacturing execution systems, a LIMS can be embedded in a complex IT-infrastructure.
[16]
lead Compound (or compound series) that satisfies predefined minimum criteria for further structure and activity optimization.
Note:
Typically, a lead will demonstrate appropriate activity, selectivity, tractable structure-activity relationship (SAR), and demonstrated activity in a relevant cell-based assay.
lead identification
Process that is targeted toward the generation of at least one compound series that meets the requirements for progression to lead optimization.
Note:
Typically, it encompasses the steps from the detection of initial activity (via highthroughput screening and other lead-finding activities) through hit confirmation and hitto-lead activities.
lead optimization
Process in which the drug-like properties of an initial lead or lead series are improved.
Note:
Typically, biological activity will be enhanced, in vivo efficacy will be demonstrated, and compounds with a physicochemical, pharmacological, and toxicological profile consistent with progression to the clinic will be identified.
library (in biomolecular screening) 1.
Collection of samples (e.g., chemical compounds, natural products, over-expression library of a microbe) available for screening.
2.
Set of compounds produced through combinatorial chemistry or other means that expands around a single core structure. 
luminescence assay
Assay in which response is measured by the detection of light of a nonradiative origin, such as bioluminescence or chemiluminescence. Example: A luciferase reporter system for the measurement of gene transcription regulation in which luciferase, transcribed under the regulation of a promoter, oxidizes the substrate luciferin to oxyluciferin. In this process, light of wavelength 560 nm is emitted and detected as the signal.
Michaelis constant, K m Substance concentration of substrate at which the rate of reaction is equal to one-half of the limiting rate (maximum rate). 
microarray (in biomolecular screening) Planar surface where assay reagents and samples are distributed as sub-microliter drops.
Note:
This screening format is a direct offshoot of genomic microarray technologies and makes use of ultra-low-volume miniaturization provided by nanodispensing technologies.
microplate
Any of a number of plates containing a series of wells which may be used for storage or to perform individual assays. J. PROUDFOOT et al. © 2011 , IUPAC Pure Appl. Chem., Vol. 83, No. 5, pp. 1129 -1158 , 2011 1148
module (in biomolecular screening) Individual automated device within a fully automated assay system that usually performs a complete single assay step or procedure.
Note:
A fully enclosed module may allow for the control of temperature, humidity, and the gaseous environment.
molecular imprinted polymers (MIPs)
Synthetic polymers in which well-defined volume cavities (imprints) created by template molecules mimic a biomolecular specific ligand-receptor interaction.
Note 1: These artificially generated recognition sites have shapes, sizes, and functionalities complementary to the template molecule, and are capable of rebinding the template molecule in preference to other closely related structures.
Note 2: MIPs have found uses as stationary phases in chromatography, as recognition elements in chemosensors, and as enzyme mimics in catalysis [17] .
multiplex assay
Assay in which the activity of a single sample against more than one target is measured in a single test.
natural product 1.
Complex mixture derived from natural (biological) sources used in screening as a resource for identification of lead compounds.
2.
Pure compound of natural (biological) origin (whether obtained by purification of natural mixtures or by laboratory synthesis), as opposed to compounds originating from synthetic chemistry.
Note:
Typical origins include extracts from microbes and higher organisms from terrestrial or marine environments.
negative assay control low control Experimental conditions designed to produce the signal reflective of the absence of the process under investigation.
For a binding or an activation mechanism, it is typically the signal measured in the absence of a test compound and is often relevant to the determination of the background signal. For an inhibitory or antagonist mechanism, it is the maximal signal, obtained in the absence of the reference inhibitor.
ultra-high throughput (in biomolecular screening) Relative term, currently applied to the screening of 10 5 test samples in a 24-h period. See also throughput, high throughput.
voltage-activated channel
Ion channel that is specifically activated, or gated, by the surrounding potential difference across the cell membrane near the channel (or near the cell, neuron, or synapse).
workstation Programmable device used to automate a single operation (such as liquid handling) on a microplate supplied to the device by a robot (automated stacker system or a robotic manipulator). [20] Z factor Dimensionless statistical parameter that provides a practical assessment of assay performance in the presence of test compounds.
where μ s denotes the mean of the library sample signal, μ c the mean of the control signal and σ s , σ c the corresponding standard deviations. 1 > Z ≥ 0.5 generally categorizes an excellent assay. [21] Z' factor Dimensionless statistical parameter used extensively in biomolecular screening, and a characteristic of an assay without the intervention of test compounds. It provides a practical index of the quality and reliability of the assay, and can be used as a guide to assay development and optimization.
Z' = 1 -3(σ c+ + σ c-)/(|μ c+ -μ c-|) where σ c+ and σ c-are the standard deviations of the high and low controls and μ c+ and μ c-are the means of the high and low controls, respectively.
Note:
The useful range of Z' values is from 0 (very poor) to +1 (excellent). In most cases, a Z' factor greater than 0.5 is required for an assay to be accepted for high-throughput screening.
[21] A graphical illustration of the parameters used in the calculation of Z' is provided below.
